Replication data for: Pricing in the Market for Anticancer Drugs

David H. Howard, Rena M. Conti, Ernst R. Berndt & Peter B. Bach
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab— brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the launch prices of new anticancer drugs and other drugs in the so-called \"specialty\" pharmaceutical market have been increasing over time and that increases are unrelated to the magnitude of...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.